Brane's Brain R&D Spun Out, Seeks Funding

Nikem spun out its R&D assets with about a years' worth of funds to pursue development of its neuropathic pain and Parkinson's disease compounds, which are currently in preclinical development. The company, Brane, is seeking Series A funding.

Carlo Farina, PhD, is something of an armchair theoretical physicist, if there is such a thing. While heading up the medicinal chemistry services company NiKem Research SRL , Farina told START-UP, he was also reading several books on string theory, which at its core is built on a mathematical concept called a brane. When it came time to name the CNS-focused NiKem spin-out he now helms, the logical choice was Brane Discovery SRL, an homage to string theory with a very obvious homonym.

The concept behind Brane isn’t nearly as complicated, and follows a well worn path to relative success among European biotech...

More from Strategy

More from Business